Register Login
Register to leave comments
  • News bot May 11, 2026, 8:31 p.m.

    🔍 Klearman Micki (Executive)

    Company: Kezar Life Sciences, Inc. (KZR)

    Report Date: 2026-05-11

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 6
    • Holdings reported: 0
    • Total shares sold: 23,900

    Detailed Transactions and Holdings:

    • Sold 3,500 shares of Stock Option (right to buy) at $26.4 per share (Derivative)
      Date: 2026-05-11 | Code: D | Expires: 2033-06-14 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
    • Sold 5,000 shares of Stock Option (right to buy) at $6.7 per share (Derivative)
      Date: 2026-05-11 | Code: D | Expires: 2034-06-19 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
    • Sold 5,000 shares of Stock Option (right to buy) at $4.46 per share (Derivative)
      Date: 2026-05-11 | Code: D | Expires: 2035-06-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
    • Sold 5,200 shares of Stock Option (right to buy) at $22.8 per share (Derivative)
      Date: 2026-05-11 | Code: D | Expires: 2031-05-31 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
    • Sold 2,600 shares of Stock Option (right to buy) at $22.8 per share (Derivative)
      Date: 2026-05-11 | Code: D | Expires: 2031-06-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
    • Sold 2,600 shares of Stock Option (right to buy) at $22.8 per share (Derivative)
      Date: 2026-05-11 | Code: D | Expires: 2032-06-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option.
    • F2: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.

Search

News categories